A federal judge in Trenton has dismissed antitrust claims against drug makers Pfizer Inc. and Ranbaxy Pharmaceuticals Inc. over a deal the two companies struck to delay production of a generic version of the popular statin drug Lipitor.
U.S. District Judge Peter Sheridan said drug wholesalers and retailers who sued Pfizer and Ranbaxy failed to prove that the defendants engaged in anticompetitive conduct when they struck the deal that postponed the launch of generic Lipitor.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
